Philadelphia biotech firm raises $14.2M to advance potential Parkinson's disease therapy
September 18, 2020 at 11:58 AM EDT
The company's goal is to be the first to develop a drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative diseases.
